$15 drug gets COVID patients off oxygen support in under week – study

Fenofibrate could dramatically shorten the treatment time for severe COVID patients


-- Jerusalem Post, --August 24, 2021

| Comments | Reader Friendly | Subscribe | Email Us


Fourteen out of 15 severe COVID-19 patients who were treated in an investigator-initiated interventional open-label clinical study of the drug TriCor (fenofibrate) didn’t require oxygen support within a week of treatment and were released from the hospital, according to the results of a new Hebrew University of Jerusalem study. Fenofibrate is an FDA-approved oral medication. The results were published on Researchsquare.com and are currently under peer review.-- More...

View Comments

News on the Net——

News from around the world